Congress opens addiction treatment to remote prescribing, removing travel barriers

What it does

This bill amends the Controlled Substances Act to allow doctors to conduct telehealth evaluations (remote video or phone consultations) as an alternative to in-person visits when prescribing FDA-approved addiction medications in schedules III–V. Currently, federal law requires at least one in-person medical evaluation before any controlled-substance prescription for substance use disorder; this bill permits that first evaluation to happen via telehealth instead, removing a barrier to remote addiction treatment.

Why we flagged it

The bill's operative mechanism is a straightforward removal of a federal barrier to remote addiction treatment. It expands access to FDA-approved medications for substance use disorder by permitting telehealth for the initial evaluation, consistent with modern telemedicine practice and public-health goals around addiction treatment.

What the text implies

• State law still governs telehealth practice standards and prescriber licensing; this bill does not preempt state restrictions, so access gains depend on state-level adoption and regulatory clarity.
• The bill permits telehealth only for FDA-approved addiction medications in schedules III–V; it does not extend to schedule II substances (e.g., buprenorphine in some formulations) or non-controlled addiction treatments, leaving some treatment pathways unchanged.
• Prescriber qualifications, DEA registration, and state medical licensing remain unchanged; the bill does not lower the bar for who can prescribe, only where the initial evaluation occurs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens with substance use disorder gain expanded access to addiction treatment by removing the requirement to travel for an in-person visit before receiving medication. This is particularly beneficial for rural, homebound, or transportation-limited patients. The bill does not weaken prescriber qualifications, FDA approval requirements, or state law — it only permits the initial evaluation to occur remotely using secure telecommunications.

Who stands to gain

• telehealth platforms and providers offering addiction treatment services
• healthcare systems and clinics expanding remote addiction-medicine capacity

Named in the bill

Controlled Substances Act, Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), Social Security Act § 1834(m), Schedule III, IV, V controlled substances, Substance use disorder treatment providers

Where it stands

31 cosponsors: 23 Democrats, 8 Republicans.

• Feb 26, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 26, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $4,260,000 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Donald Norcross, the sponsor, reported $841,914 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• American Association of Nurse Practitioners — $950,000 on 2 filings
• Alliance for Connected Care — $200,000 on 1 filing
• Ata Action — $60,000 on 2 filings
• Ata Action — $40,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.